Patient feedback on low-grade brain tumor treatment
Treatments studied
Part of Cancer clinical trials.
This study asks patients with a specific type of low-grade brain tumor (IDH mutant grade 2 glioma) to share their experiences and quality of life while receiving a treatment called vorasidenib, with or without radiation. Your feedback helps doctors understand how well the treatment works from your perspective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with IDH mutant grade 2 glioma (a type of low-grade brain tumor)
- You are willing to receive the study treatment (vorasidenib and/or radiotherapy)
- You can understand and complete quality-of-life questionnaires in the trial's language
- You do not have severe cognitive impairment, untreated mental health conditions, or language barriers that would prevent you from answering survey questions accurately
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug vorasidenib for people with a slow-growing brain tumor (Grade 2 glioma) that has an IDH mutation. The goal is to see how well the drug works and how it affects your quality of life.
This trial tests whether the drug vorasidenib, guided by a special PET scan, can help people with certain low-grade brain tumors that have come back or are still present after surgery. It aims to see if this approach is safe and effective.
This study records health details about adults who may have a low-grade glioma (a slower-growing brain tumor) based on scan results. Researchers use these data to better understand disease patterns and outcomes, and help connect individual patients to future research.
This Phase 1 study tests vorasidenib combined with a personalized tumor-targeting peptide vaccine in adults with a specific type of recurrent brain tumor. It aims to see how safe the combination is and whether it can help slow the tumor’s growth.
This trial studies how radiotherapy affects memory and thinking in adults with certain brain or skull-base tumors. It may help doctors understand who is most likely to have thinking changes and how to monitor or support patients.
This trial tests whether taking vorasidenib after standard radiation and chemotherapy can help prevent low-grade IDH-mutant astrocytoma from growing back. It is for people who have completed first-line therapy and whose tumors have not progressed.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.